




Objective: To evaluate post-stroke outcomes in patients with Parkinson’s disease (PD) 
Methods: A matched cohort study was performed. Stroke patients with PD and non-PD 
controls were extracted from the Thailand Universal Insurance Database. Logistic regressions 
were used to evaluate the association between PD and in-hospital outcomes (mortality and 
complications). The PD-associated long-term mortality was evaluated using Royston-Parmar 
models. 
Results: 1,967 patients with PD were identified between 2003 and 2015 and matched to 
controls (1:4) by age, sex, admission year, and stroke type. PD patients had decreased odds of 
in-hospital death: OR (95% CI) 0.66 (0.52 – 0.84) and 0.61 (0.43 – 0.85) after ischaemic and 
haemorrhagic strokes, respectively. PD was associated with a length-of-stay greater than 
median (4 days) after both stroke types: 1.37 (1.21 – 1.56) and 1.45 (1.05 – 2.00), 
respectively. Ischaemic stroke patients with PD also had increased odds of developing 
pneumonia, sepsis and AKI: 1.52 (1.2 – 1.83), 1.54 (1.16 – 2.05), and 1.33 (1.02 – 1.73). In 
haemorrhagic stroke patients, PD was associated with pneumonia: 1.89 (1.31 – 2.72). 
Survival analyses showed that PD was protective against death in the short term (HR=0.66; 
95% CI 0.53–0.83 ischaemic, and HR=0.50; 95% CI 0.37 – 0.68 haemorrhagic stroke), but 
leads to an increased mortality risk approximately 1 and 3 months after ischaemic and 
haemorrhagic stroke, respectively. 
Conclusion: PD is associated with a reduced mortality risk during the first 2-4 weeks post-
admission but an increased risk thereafter, in addition to increased odds of in-hospital 





Despite previous studies having evaluated the incidence of stroke in people with co-
morbid Parkinson’s Disease (PD)[1-4], the relationship between these two disabling 
neurological conditions remains controversial. Although the most recent studies suggest a 
positive association between PD and stroke risk, the impact of pre-existing PD on stroke 
outcomes has not yet been investigated. Furthermore, there are two streams of translational 
evidence regarding the relationship of PD and stroke on a molecular level. On one hand, it 
has been shown that in PD, neurons may be more vulnerable to ischaemic damage due to 
their disease-mediated impaired ability to withstand oxidative stress[5,6]. Oxidative stress is 
recognised to be implicated in the pathophysiology of both stroke and PD[7,8], and therefore, 
it may thus be the case that patients with PD have worse stroke outcomes than those without 
PD. On the other hand however, previous experimental models have shown that cerebral 
ischaemia provokes an acute exaggerated release of dopamine, which leads to excess 
neuronal degeneration[9]. This effect has not been observed in in vivo models in which 
dopamine release is impaired[10]. Thus, in the context of this phenomenon, it is possible that 
PD-associated hypodopaminergia could protect neurons from excess damage during 
ischaemic events, and thus result in less severe stroke outcomes. 
Given the lack of literature regarding the prognosis of stroke in patients with PD, we 
aimed to evaluate the impact of co-morbid PD on the outcomes of stroke using a 






 Data for this matched control study was extracted from the Universal Coverage (UC) 
Health Security Insurance Scheme Database of Thailand. This database contains clinical and 
demographic data of 615,758 patients admitted with a stroke diagnosis between 2003 and 
2015 in all eligible healthcare centres in Thailand, covering ~ 80% of the Thai population. 
Admissions, co-morbidities, and complications were registered using ICD10 (International 
Classification of Disease, tenth revision) codes (Supplementary Table 1). Further details 
about this database can be found in our previously published studies[11,12].  
 
Compliance with Ethical Standards 
Ethical approval was obtained from the Ethics Committee in Human Research, Khon 
Kaen University, Khon Kaen, Thailand. Our study protocol conforms to the ethical guidelines 
of the 1975 Declaration of Helsinki and its later amendments or comparable ethical standards. 
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. There are no conflict of interest or funding sources to declare. 
 
Patient Population and Match Selection 
We performed a matched cohort study of patients with co-morbid PD admitted with a 
stroke diagnosis against patients without PD admitted with the same diagnosis (unexposed 
controls). PD patients and their controls were extracted from a pool of 608,890 stroke patients 
(ICD10 codes I61 (Haemorrhagic Stroke), I63 (Ischaemic Stroke), I64 (Stroke of 
Undetermined Pathology)), obtained after the exclusion of patients younger than 18 years of 
age (n = 1427), those older than 100 years (n = 43) and those with missing post-discharge 
follow-up data (n = 5398, 0.88% of total eligible sample). Pre-existing co-morbidities, 
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demographic and clinical data were extracted from the database as detailed in Supplementary 
Table 1. The exposed population was identified as all patients recorded to have PD (ICD10 
code G20; n = 1970) as a co-morbidity on stroke admission. For each exposed patient, we 
randomly selected 4 unexposed controls matched by age, sex, year of admission, and stroke 
type, yielding a total of 1,967 exposed and 7,868 unexposed controls after excluding those 
with insufficient number of matches (n = 3) (Supplementary Figure 1). 
 
Statistical Analysis 
Descriptive Statistics  
Stroke type-specific demographic and clinical characteristics were compared between 
those with co-morbid PD and the matched controls using the independent-sample t-test for 
normally distributed continuous variables, the Mann-Whitney U test for non-normally 
distributed continuous variables and the Chi-squared test for categorical variables.  
 
Analysis of in-hospital adverse events 
Multivariable logistic regression models were constructed to evaluate the effect of co-
morbid PD on in-hospital mortality and adverse events. We evaluated post-stroke adverse 
events deemed to be relevant (length of stay in hospital (LOS) greater than median, 
pneumonia, sepsis, respiratory failure, and acute kidney injury) based on a reference list of 
most common and serious post-stroke adverse events by Hesse et al[13]. All models were 
adjusted for potential confounders of adverse events post-stroke in line with previous reports 
(hypertension, hyperlipidaemia, ischaemic heart disease, atrial fibrillation, heart failure, 
diabetes mellitus, malignancy, chronic kidney disease, chronic obstructive pulmonary 
disease, liver disease and alcohol related illness)[11,14,15]. Additionally, we adjusted for 
occurrence of the adverse events listed above as potential confounders. Covariates were 
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incorporated into the regressions using a bidirectional step-wise selection model with 
inclusion and exclusion thresholds of 5% and 20%, respectively. All models were adjusted 
for the covariates which reached the inclusion criteria during the stepwise selection.  
 
Analysis of post-discharge mortality 
Post-discharge mortality was evaluated for ischaemic and haemorrhagic strokes 
separately. Strokes of undetermined pathology were excluded from this part of the analysis 
due to the impossibility of extrapolating these results in the long-term. This outcome was 
compared between the exposed and unexposed using a flexible parametric restricted cubic 
spline (Royston-Parmar) survival regression[16]. Both models were adjusted for all 
covariates used in the analyses evaluating the in-hospital outcomes. Median follow-up time 
was estimated using the reverse Kaplan-Meier method[17].  
 
Post-hoc analysis 
To complement the results obtained from our pre-determined analyses, we decided to 
model mortality using date of admission instead of discharge date as the start of follow-up in 
order to better demonstrate the effects we observed during the hospitalisation period. We 
constructed Royston-Parmar models for both ischaemic and haemorrhagic strokes as those 





In total, 1970 patients with known PD were identified within this cohort 
(Supplementary Figure 1). Of these cases, 3 could not be matched with 4 controls as per a 
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priori defined matching variables, and were therefore excluded. A summary of patient 
characteristics and comorbidities are depicted in Table 1. We found statistically significant 
differences in prevalence of some comorbidities between the two groups, as well as 
significant differences in length of hospital stay.  
Descriptive data regarding in-hospital complications and in-hospital mortality are 
detailed in Table 2.  For all stroke types, a smaller proportion of patients with PD died in 
hospital compared to their controls (9.35% vs. 12.02%, p<0.001). Additionally, more PD 
patients had a length of stay greater than median (4 days) compared to controls (48.65% vs. 
38.97%, p<0.001), and a greater proportion of PD patients developed pneumonia (15.66% vs. 
10.50%, p<0.001), sepsis (5.29% vs. 3.13%, p<0.001), and acute kidney injury (AKI) (5.74% 
vs. 3.77%, p<0.001).  
 
Post-Stroke Adverse Events 
The results of the multivariable logistic regression are reported in Figure 1. Patients 
with PD presenting with an ischaemic stroke had significantly reduced odds of death in 
hospital (OR=0.66; 95% CI, 0.52-0.84) despite having higher odds of pneumonia (OR=1.52; 
95% CI, 1.27 - 1.83), sepsis (OR=1.54; 95% CI, 1.16 – 2.05), and AKI (OR=1.33; 95% CI, 
1.02 – 1.73), and increased odds of having a length of hospital stay greater than median 
(OR=1.37; 95% CI, 1.21 - 1.56). Patients with PD presenting with a haemorrhagic stroke had 
lower odds of in-hospital mortality (OR=0.61; 95% CI, 0.43 - 0.85), and were more likely to 
develop pneumonia (OR=1.89; 95% CI, 1.31 - 2.72) and to have greater than median LOS 
(OR=1.45; 95% CI, 1.05 - 2.00). Lastly, patients with PD presenting with strokes of 






The results of the survival regression models of post-discharge mortality for each 
stroke type are depicted in Figure 2A and 2B. The median follow-up time was 3.7 (95% CI: 
3.6 – 3.8) and 4.0 (95% CI: 3.4 – 4.5) years for patients with ischaemic and haemorrhagic 
strokes, respectively. Patients with PD in both stroke categories had an increased mortality 
risk compared to their unexposed controls in the long term. For ischaemic strokes, this 
increased risk appeared after the 34th day post-discharge (HR=1.20; 95% CI, 1.02 – 1.42). 
The HR function then remains approximately constant throughout the follow-up period 
(HR=1.50; 95% CI, 1.26 – 1.80). For haemorrhagic strokes, mortality risk reached statistical 
significance after ~ 6 months (188 days) (HR=1.38; 95% CI, 1.00 – 1.91), and was double 
that of controls at the end of the 12-year follow-up period (HR=1.98; 95% CI, 1.12 – 3.48).  
 
Post-hoc analysis 
The results of the survival regression models of post-admission mortality for each 
stroke type are depicted in Figure 2C and 2D. After ischaemic stroke, PD was associated with 
a decreased risk of mortality up to the 12th day post admission (range from HR=0.66; 95% CI 
0.53 – 0.83 at day 3 to HR=0.90; 95% CI 0.77 – 1.05 at day 13). After this period, there is no 
significant difference in mortality between patients with PD and controls until day 36, at 
which point PD patients show an increased mortality risk (HR=1.18; 95% CI 1.02 – 1.37). 
Similarly, after haemorrhagic strokes, PD patients have a decreased risk of mortality up to the 
22nd day post-admission (ranging from HR=0.50; 95% CI 0.37 – 0.68 on day 3 to HR=0.76; 
95% CI 0.56 – 1.03 on day 23). Following this period, mortality between them and controls is 
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no different until day 106, after which PD is associated with an increased mortality risk 
(HR=1.26; 95% CI 1.00 – 1.58). 
DISCUSSION 
To the best of our knowledge, we are the first study to report on the outcomes of 
stroke in patients with PD. We have found that these patients were less likely to die during 
the acute phase despite having higher odds of some common post-stroke complications. 
Additionally, they were more likely to stay in hospital longer than controls. PD patients had 
higher odds of pneumonia regardless of stroke type, and sepsis and AKI after an ischaemic 
stroke. Our survival analyses showed that PD is associated with an increased risk of long-
term mortality after stroke. 
In the present study, we have shown that patients with PD were 35% and 42% less 
likely to die in hospital after ischaemic and haemorrhagic strokes, respectively. This 
protective effect was short-lived, disappearing 13 days after admission in the ischaemic 
stroke sub-group and 22 days after admission in the haemorrhagic stroke sub-group. After 
this ‘protective window’, the post-stroke PD-associated mortality excess risk was not 
significant until 36 and 106 days after admission for ischaemic and haemorrhagic strokes, 
respectively. From then onwards, the PD-associated excess mortality risk becomes significant 
and increases from 20% to 57% during the 12-year follow-up period after ischaemic stroke, 
and from 38% to 98% increased risk after haemorrhagic stroke. 
Our results may be interpreted in the context of the effects of stroke on the 
dopaminergic system[9] and the inherent sensitivity of neurons to ischaemia observed in PD 
models[5,6,8]. A possible mechanism for the PD-associated protective effect on acute 
mortality after stroke may be the lack of dopamine-induced neuronal damage during the 
course of ischaemia in the brain. A recent review by Gower & Tiberi on the effects of stroke 
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on the dopaminergic system found that many experimental studies have reported an 
exaggerated release of dopamine into the striatum immediately after stroke[9].  It is argued 
that this has a detrimental effect on neurons, as models in which dopamine release is inhibited 
showed protection from excess ischaemic damage[10]. Thus, it is possible that due to the 
inherent dopaminergic dysfunction of PD, the exaggerated dopamine release does not take 
place and consequently, no excess ischaemic damage occurs. Nevertheless, after the acute 
period, our study shows that the PD is associated with excess mortality, which increases with 
time. This may indicate that the potential to avoid dopamine-induced damage early may not 
translate to a reduction in mortality in the longer term. Still, these mechanisms and their 
interaction with the clinical course of patients with PD after stroke is a subject that warrants 
further investigation. For example, to explore the potentially summative effect of dopamine-
induced damage and stroke one could consider the laterality of PD in the context of stroke 
location. There is extensive evidence to suggest that in PD, the substantia nigra and putamen 
contralateral to the dominantly-affected side show greater degeneration and reduced 
dopamine activity compared to the opposite side[18]. Therefore, it would be interesting to 
compare mortality between PD patients who have a stroke on the dominantly-affected side 
(with less dopamine activity), and those who have a stroke on the opposite side. Differences 
in outcomes between these two sub-groups could further strengthen the hypothesis that 
hypodopaminergia is protective against ischaemic injury, however in this study, we did not 
have data on PD dominance or stroke location to explore this avenue.  
We also found that patients with PD spent longer in hospital after stroke compared to 
their controls, even after adjusting for in-hospital complications. Previous studies have shown 
that amongst emergency department admissions of any cause, patients with pre-existing PD 
spent longer times in hospital than patients without[19-21]. The results of our study are in 
line with the findings of these previous reports in the context of stroke admissions. It would 
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be interesting to examine the reasons for prolonged hospitalisation, such as poorer mobility or 
more extensive intervention requirements in the PD group (physiotherapy, PD management 
optimisation, etc.). Our data did not contain information on mobility status or interventions 
post-stroke to investigate this further. 
Another finding of this report is that patients with PD are at a higher risk of 
pneumonia post stroke, and additionally, sepsis and AKI after ischaemic stroke. Respiratory 
complications have been widely reported in patients with PD throughout the literature[22]. 
Moreover, about a third of patients with PD exhibit an obstructive ventilation pattern, with 
evidence that autonomic dysfunction and abnormal muscle control result in poor clearance of 
secretions and the consequences thereof[23]. Consequently, all of these factors make patients 
with PD more susceptible to airway infections, especially aspiration pneumonia. Along with 
this increased risk, there is the added risk of respiratory infections due to stroke 
complications, most importantly dysphagia. Dysphagia is one of the highest incident 
complications of stroke and one of the most important predictors of pneumonia and aspiration 
pneumonia post-stroke[24,25]. One could hypothesise that, given the potentially poor airway 
function of PD patients, stroke-induced dysphagia may not only occur more easily, but also 
be longer lasting in these patients. Furthermore, although most patients who develop stroke-
induced dysphagia recover satisfactorily from the episode[26], the same may not be true for 
those with PD. Nevertheless, the association between PD and the susceptibility to develop 
post-stroke dysphagia and its impact on clinical outcomes is a subject requiring further 
investigation. 
Parallel to the positive association between post-stroke pneumonia and PD, we found 
that patients with PD had significantly higher odds of developing sepsis and AKI after 
ischaemic stroke. Notably, these observations remain significant even after adjusting for 
pneumonia. This suggests that stroke patients with PD are more likely to develop sepsis 
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independently of whether they developed pneumonia in ischaemic stroke. Sepsis is a 
systemic inflammatory reaction to infection and must therefore be preceded by it. Most 
patients with PD exhibit some degree of autonomic dysfunction, including disordered 
cardiovascular, gastrointestinal, respiratory, urogenital and thermoregulatory function[27]. 
There is an argument that these organ system dysfunctions may make patients with PD more 
vulnerable to acquire infections and less able to fight them once infection has 
occurred[28,29]. Similarly, it is possible patients with PD are more susceptible to AKI due to 
autonomic dysfunction of the bladder and increased incidence of infections. We hypothesise 
that these factors may make patients with PD more vulnerable to develop these complications 
after stroke.  
Our study has several strengths. We used a prospectively-identified multi-centre 
national database cohort to identify patients with co-morbid PD, minimising the potential for 
selection and recall bias. We have utilised novel flexible time-to-event models to render the 
varying nature of the PD-associated mortality risk over time. Additionally, we have described 
the length of stay and other adverse events of clinical relevance in these patients, which may 
serve as reference points for further research.  
We do acknowledge some limitations. Our case ascertainment and analyses were 
based on insurance reimbursement data classified using ICD10 codes.  This reimbursement 
database lacked clinical characteristics of diagnoses, and therefore we did not have 
information regarding disease severity such as stroke disability. In addition, the database used 
did not include information regarding pre-admission and post-discharge management, and 
thus, we were unable to investigate the effect of different treatment regimens on outcomes. 
Also, the management of PD and stroke may have changed over the twelve-year recruitment 
period. Although this remains one of the inherent limitations of long follow-up studies, we 
minimised its effect by using strict matching criteria, including year of admission as one of 
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the matching variables for controls. Finally, our data did not include information regarding 
stroke location or PD lateralisation. 
 
CONCLUSION 
Whilst the relationship between PD and stroke incidence has been previously 
explored, the effect of PD on stroke outcomes has not been examined previously. We have 
shown that PD is associated with a differential risk of post-stroke mortality depending on the 
time course. Whilst in the short-term PD has a protective effect on mortality after stroke, this 
effect is reversed 2-4 weeks thereafter. Additionally, our findings show that PD is associated 
with more adverse events and a greater length of stay during hospitalisation. These results 
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FIGURE TITLES / LEGENDS 
 
Figure 1 - Association between co-morbid PD and post-stroke adverse events, stratified by 
outcome and stroke type.  
PD = Parkinson’s Disease, OR = Odds Ratio, CI = Confidence Interval, LOS = Length Of Stay, 
AKI = Acute Kidney Injury, UTI = Urinary Tract Infection, NS = Not Significant. All ORs 
were adjusted for hypertension, hyperlipidaemia, ischaemic heart disease, atrial fibrillation, 
heart failure, diabetes mellitus, malignancy, chronic kidney disease, chronic obstructive 
pulmonary disease, liver disease and alcohol related illness according to a stepwise selection 
model. Additionally, each individual model was adjusted for all other complications.  
Figure 2 - Post-discharge (A and B) and Post-admission (C and D) excess mortality (hazard 
ratio) associated with co-morbid Parkinson's in stroke patients.  
Hazard ratio (solid line) and 95% confidence intervals (shaded area) are shown as a function 
of time. (A and C) Post ischaemic stroke. The hazard ratio was calculated as a function of 
restricted cubic splines with 2 internal knots. (B and D) Post haemorrhagic stroke. The hazard 
ratio was calculated as a function of restricted cubic splines with 2 internal knots. 
